Standard
AB1042 Dynamic contrast-enhanced magnetic resonance imaging in a randomized placebo-controlled rheumatoid arthritis trial – impact of applying joint coverage quality criteria. / Axelsen, MB; Bliddal, H; Jacobssen, LTH; Hansen, MS; Dudek, A; Rell-bakalarska, M; Boesen, M; Stefanek, J; Sundman-Engberg, B; Østergaard, M.
In:
Annals of the Rheumatic Diseases, Vol. 76, No. Suppl 2, 518, 2017, p. 1419.
Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
Harvard
Axelsen, MB
, Bliddal, H, Jacobssen, LTH, Hansen, MS, Dudek, A, Rell-bakalarska, M
, Boesen, M, Stefanek, J, Sundman-Engberg, B
& Østergaard, M 2017, '
AB1042 Dynamic contrast-enhanced magnetic resonance imaging in a randomized placebo-controlled rheumatoid arthritis trial – impact of applying joint coverage quality criteria',
Annals of the Rheumatic Diseases, vol. 76, no. Suppl 2, 518, pp. 1419.
https://doi.org/10.1136/annrheumdis-2017-eular.1946APA
Axelsen, MB.
, Bliddal, H., Jacobssen, LTH., Hansen, MS., Dudek, A., Rell-bakalarska, M.
, Boesen, M., Stefanek, J., Sundman-Engberg, B.
, & Østergaard, M. (2017).
AB1042 Dynamic contrast-enhanced magnetic resonance imaging in a randomized placebo-controlled rheumatoid arthritis trial – impact of applying joint coverage quality criteria.
Annals of the Rheumatic Diseases,
76(Suppl 2), 1419. [518].
https://doi.org/10.1136/annrheumdis-2017-eular.1946Vancouver
Axelsen MB
, Bliddal H, Jacobssen LTH, Hansen MS, Dudek A, Rell-bakalarska M et al.
AB1042 Dynamic contrast-enhanced magnetic resonance imaging in a randomized placebo-controlled rheumatoid arthritis trial – impact of applying joint coverage quality criteria.
Annals of the Rheumatic Diseases. 2017;76(Suppl 2):1419. 518.
https://doi.org/10.1136/annrheumdis-2017-eular.1946Author
Axelsen, MB ; Bliddal, H ; Jacobssen, LTH ; Hansen, MS ; Dudek, A ; Rell-bakalarska, M ; Boesen, M ; Stefanek, J ; Sundman-Engberg, B ; Østergaard, M. / AB1042 Dynamic contrast-enhanced magnetic resonance imaging in a randomized placebo-controlled rheumatoid arthritis trial – impact of applying joint coverage quality criteria. In: Annals of the Rheumatic Diseases. 2017 ; Vol. 76, No. Suppl 2. pp. 1419.
Bibtex
@article{8f825301d9634e2ea6b196964f9023bc,
title = "AB1042 Dynamic contrast-enhanced magnetic resonance imaging in a randomized placebo-controlled rheumatoid arthritis trial – impact of applying joint coverage quality criteria",
author = "MB Axelsen and H Bliddal and LTH Jacobssen and MS Hansen and A Dudek and M Rell-bakalarska and M Boesen and J Stefanek and B Sundman-Engberg and M {\O}stergaard",
year = "2017",
doi = "10.1136/annrheumdis-2017-eular.1946",
language = "English",
volume = "76",
pages = "1419",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "B M J Group",
number = "Suppl 2",
}
RIS
TY - ABST
T1 - AB1042 Dynamic contrast-enhanced magnetic resonance imaging in a randomized placebo-controlled rheumatoid arthritis trial – impact of applying joint coverage quality criteria
AU - Axelsen, MB
AU - Bliddal, H
AU - Jacobssen, LTH
AU - Hansen, MS
AU - Dudek, A
AU - Rell-bakalarska, M
AU - Boesen, M
AU - Stefanek, J
AU - Sundman-Engberg, B
AU - Østergaard, M
PY - 2017
Y1 - 2017
U2 - 10.1136/annrheumdis-2017-eular.1946
DO - 10.1136/annrheumdis-2017-eular.1946
M3 - Conference abstract in journal
VL - 76
SP - 1419
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
SN - 0003-4967
IS - Suppl 2
M1 - 518
ER -
